Comparative Pharmacology
Head-to-head clinical analysis: GLOFIL 125 versus IOBENGUANE I 123.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLOFIL 125 versus IOBENGUANE I 123.
GLOFIL-125 vs IOBENGUANE I-123
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GLOFIL-125 (pentoxifylline) is a xanthine derivative that improves erythrocyte flexibility by inhibiting phosphodiesterase, leading to increased intracellular cAMP. It also reduces blood viscosity and platelet aggregation, improving microcirculation.
Iobenguane I-123 is a radiopharmaceutical analog of norepinephrine that is taken up by adrenergic neurons and neuroendocrine tumors via the norepinephrine transporter (NET). It localizes in tissues rich in sympathetic innervation and tumors expressing NET, enabling scintigraphic imaging.
125 mg orally twice daily.
Intravenous administration of 5 mCi (185 MBq) as a single dose for imaging.
None Documented
None Documented
Terminal elimination half-life: 2.5–3.5 hours (prolonged in renal impairment; up to 20–30 hours in severe chronic kidney disease).
Terminal elimination half-life: 5-7 hours; clinically relevant for imaging timing (optimal scanning at 24 hours post-injection)
Renal excretion of unchanged drug >90%; biliary/fecal <5%.
Renal: 40-60% as unchanged iobenguane within 24 hours; biliary/fecal: minimal (<5%)
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical